Litt’s Drug profile for Revefenacin

  • Trade Name: Yupelri (Theravance Biopharma)
  • Indications: indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
  • Class: Anticholinergic
  • Half-life: 22–70 hours
  • FDA Approval Date: 11/09/2018
  • Clinically important, potentially hazardous interactions with:
    Cyclosporine
  • Pregnancy: No adequate studies conducted. Advised to contact physician if pregnancy occurs while taking drug.

Please login to view the rest of this drug profile.

Page last updated 08/20/2025

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric